Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium-Reference-Cited by-同舟云学术

Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium

Published:2018-10-22 Issue:5 Volume:104 Page:836-864
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Chu Xiaoyan¹,Liao Mingxiang²,Shen Hong³,Yoshida Kenta⁴^ORCID,Zur Arik A.⁵,Arya Vikram⁶^ORCID,Galetin Aleksandra⁷,Giacomini Kathleen M.⁸^ORCID,Hanna Imad⁹,Kusuhara Hiroyuki¹⁰,Lai Yurong¹¹^ORCID,Rodrigues David¹²,Sugiyama Yuichi¹³^ORCID,Zamek-Gliszczynski Maciej J.¹⁴,Zhang Lei¹⁵,

Affiliation:

1. Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism; Merck & Co., Inc; Kenilworth New Jersey USA

2. Department of Clinical Pharmacology; Clovis Oncology, Inc.; Boulder Colorado USA

3. Department of Metabolism and Pharmacokinetics; Bristol-Myers Squibb; Princeton New Jersey USA

4. Clinical Pharmacology; Genentech Research and Early Development; South San Francisco California USA

5. BiolineRX; Modi'in Israel

6. Division of Clinical Pharmacology IV; Office of Clinical Pharmacology; Office of Translational Sciences; Center for Drug Evaluation and Research; Food and Drug Administration; Silver Spring Maryland USA

7. Centre for Applied Pharmacokinetic Research; School of Health Sciences; University of Manchester; Manchester UK

8. Department of Bioengineering and Therapeutic Sciences; Schools of Pharmacy and Medicine; University of California; San Francisco California USA

9. Pharmacokinetic Sciences; Novartis Institutes for Biomedical Research; East Hanover New Jersey USA

10. Graduate School of Pharmaceutical Sciences; The University of Tokyo; Tokyo Japan

11. Drug Metabolism; Gilead Science, Inc.; Foster City California USA

12. Pharmacokinetics, Dynamics, & Metabolism; Medicine Design; Pfizer Inc.; Groton Connecticut USA

13. Sugiyama Laboratory; RIKEN Baton Zone Program, Cluster for Science; RIKEN; Yokohama Japan

14. Quantitative Drug Disposition; GlaxoSmithKline PLC; King of Prussia Pennsylvania USA

15. Office of Research and Standards; Office of Generic Drugs; Center for Drug Evaluation and Research; Food and Drug Administration; Silver Spring Maryland USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpt.1216/fullpdf

Reference110 articles.

1. Membrane transporters in drug development;Giacomini;Nat. Rev. Drug Discov.,2010

2. Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium;Tweedie;Clin. Pharmacol. Ther.,2013

3. Evaluation of transporters in drug development: current status and contemporary issues;Lee;Adv. Drug Deliv. Rev.,2017

4. In vitro-in vivo extrapolation of metabolism- and transporter-mediated drug-drug interactions-overview of basic prediction methods;Yoshida;J. Pharm. Sci.,2017

Cited by 140 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative prediction of transporter-mediated drug-drug interactions using the mechanistic static pharmacokinetic (MSPK) model;Drug Metabolism and Pharmacokinetics;2024-02

2. Membrane transporters in drug development and as determinants of precision medicine;Nature Reviews Drug Discovery;2024-01-24

3. Effect of probenecid on blood levels and renal elimination of furosemide and endogenous compounds in rats: Discovery of putative organic anion transporter biomarkers;Biochemical Pharmacology;2023-12

4. The Effect of BI 730357 (Retinoic Acid‐Related Orphan Receptor Gamma t Antagonist, Bevurogant) on the Pharmacokinetics of a Transporter Probe Cocktail, Including Digoxin, Furosemide, Metformin, and Rosuvastatin: An Open‐Label, Non‐randomized, 2‐Period Fixed‐Sequence Trial in Healthy Subjects;Clinical Pharmacology in Drug Development;2023-11-13

5. Utilization of OATP1B Biomarker Coproporphyrin‐I to Guide Drug–Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry;Clinical Pharmacology & Therapeutics;2023-10-11